Sandy Spring Bank Abb Vie Inc. Transaction History

Sandy Spring Bank

$2.4 Billion
Q3 2024

A detailed history of Sandy Spring Bank transactions in Abb Vie Inc. stock. As of the latest transaction made, Sandy Spring Bank holds 37,599 shares of ABBV stock, worth $6.77 Million. This represents 0.31% of its overall portfolio holdings.

Number of Shares

37,599

Previous 37,608 0.02%

Holding current value

$6.77 Million

Previous $6.45 Million 15.12%

% of portfolio

0.31%

Previous 0.29%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 25, 2024	SELL	$163.84 - $199.33 $1,474 - $1,793	-9 Reduced 0.02%	37,599 $7.43 Million
Q2 2024 Aug 06, 2024	SELL	$154.79 - $180.76 $150,610 - $175,879	-973 Reduced 2.52%	37,608 $6.45 Million
Q1 2024 May 08, 2024	SELL	$159.82 - $182.1 $217,035 - $247,291	-1,358 Reduced 3.4%	38,581 $7.03 Million
Q4 2023 Jan 26, 2024	SELL	$137.6 - $154.97 $569,113 - $640,955	-4,136 Reduced 9.38%	39,939 $6.19 Million
Q3 2023 Oct 30, 2023	SELL	$133.59 - $154.65 $217,885 - $252,234	-1,631 Reduced 3.57%	44,075 $6.57 Million
Q2 2023 Aug 04, 2023	SELL	$132.51 - $164.9 $395,674 - $492,391	-2,986 Reduced 6.13%	45,706 $6.16 Million
Q1 2023 May 05, 2023	SELL	$144.61 - $166.54 $30,512 - $35,139	-211 Reduced 0.43%	48,692 $7.76 Million
Q4 2022 Feb 10, 2023	BUY	$138.31 - $165.87 $1.15 Million - $1.38 Million	8,300 Added 20.44%	48,903 $7.91 Million
Q3 2022 Nov 02, 2022	SELL	$134.21 - $153.93 $381,961 - $438,084	-2,846 Reduced 6.55%	40,603 $5.45 Million
Q2 2022 Jul 21, 2022	SELL	$137.62 - $174.96 $104,453 - $132,794	-759 Reduced 1.72%	43,449 $6.66 Million
Q1 2022 May 03, 2022	SELL	$131.98 - $163.75 $263 - $327	-2 Reduced -0.0%	44,208 $7.17 Million
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $20,196 - $25,554	188 Added 0.43%	44,210 $5.99 Million
Q3 2021 Nov 05, 2021	SELL	$106.4 - $120.78 $178,858 - $203,031	-1,681 Reduced 3.68%	44,022 $4.75 Million
Q2 2021 Aug 09, 2021	BUY	$105.21 - $117.21 $88,376 - $98,456	840 Added 1.87%	45,703 $5.15 Million
Q1 2021 May 03, 2021	SELL	$102.3 - $112.62 $281,120 - $309,479	-2,748 Reduced 5.77%	44,863 $4.86 Million
Q4 2020 Feb 03, 2021	SELL	$80.49 - $108.67 $75,580 - $102,041	-939 Reduced 1.93%	47,611 $5.1 Million
Q3 2020 Nov 09, 2020	SELL	$85.91 - $100.83 $26,030 - $30,551	-303 Reduced 0.62%	48,550 $4.25 Million
Q2 2020 Aug 12, 2020	BUY	$73.37 - $98.18 $136,394 - $182,516	1,859 Added 3.96%	48,853 $4.8 Million
Q1 2020 May 01, 2020	SELL	$64.5 - $97.79 $137,449 - $208,390	-2,131 Reduced 4.34%	46,994 $3.58 Million
Q4 2019 Feb 06, 2020	SELL	$72.13 - $90.25 $181,479 - $227,069	-2,516 Reduced 4.87%	49,125 $4.35 Million
Q3 2019 Nov 01, 2019	SELL	$62.98 - $75.72 $81,307 - $97,754	-1,291 Reduced 2.44%	51,641 $3.91 Million
Q2 2019 Aug 01, 2019	SELL	$65.7 - $83.98 $448,665 - $573,499	-6,829 Reduced 11.43%	52,932 $3.85 Million
Q1 2019 May 06, 2019	SELL	$77.14 - $90.79 $3.2 Million - $3.76 Million	-41,463 Reduced 40.96%	59,761 $4.82 Million
Q4 2018 Feb 08, 2019	SELL	$77.85 - $96.01 $623,734 - $769,232	-8,012 Reduced 7.33%	101,224 $9.33 Million
Q3 2018 Nov 07, 2018	SELL	$88.91 - $98.84 $156,303 - $173,760	-1,758 Reduced 1.58%	109,236 $10.3 Million
Q2 2018 Aug 03, 2018	BUY	$89.78 - $106.23 $181,624 - $214,903	2,023 Added 1.86%	110,994 $10.3 Million
Q1 2018 May 04, 2018	SELL	$92.01 - $123.21 $65,695 - $87,971	-714 Reduced 0.65%	108,971 $10.3 Million
Q4 2017 Feb 02, 2018	BUY	$89.56 - $98.21 $9,582 - $10,508	107 Added 0.1%	109,685 $10.6 Million
Q3 2017 Nov 03, 2017	SELL	$69.85 - $89.22 $93,319 - $119,197	-1,336 Reduced 1.2%	109,578 $9.74 Million
Q2 2017 Aug 11, 2017	BUY	N/A	110,914	110,914 $8.08 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandy Spring Bank, based on Form 13F filings with the SEC.

News

Stay updated on Sandy Spring Bank with notifications on news.

Account

Sandy Spring Bank Abb Vie Inc. Transaction History